In this capacity, Dr Sadeh will play a significant role in advancing the clinical development of Scinai's lead IL-17 program along with other promising assets in their unique VHH antibody pipeline.
Dr. Sadeh is an accomplished physician-scientist with over 20 years of experience in drug development and clinical research. He spent the last five years at Bristol-Myers Squibb (BMS), where he held multiple senior leadership positions, including Senior Vice President and Global Programs Head for Immunology, Cardiovascular, and Neuroscience; Immunology Therapeutic Area Head; and China R&D Head.
Throughout his career, he has been responsible for multiple drug approvals across various fields, including pulmonary, rheumatology, dermatology, gastroenterology, and neurology. His most recent achievement is the approval of Sotyktu, a first-in-class TYK2 inhibitor for the treatment of psoriasis. Prior to BMS, Dr. Sadeh held senior leadership positions at Sanofi, AstraZeneca, and Schering-Plough.
Dr. Sadeh earned his MD in Medicine from the Mount Sinai School of Medicine and an M.Sc. degree in Clinical Research from Harvard Medical School. He completed his fellowship in pulmonary and critical care at Harvard Medical School. He began his medical career as an academic researcher at Brigham and Women's Hospital.
Dr. Jonathan Sadeh commented: "As a physician, scientist, and drug developer, I am deeply committed to advancing innovative therapies for patients with significant unmet medical needs. Scinai's use of VHH antibodies as a bio-better approach leverages the unique attributes of VHH antibodies to overcome the shortcomings of other approved biologics. This presents a unique way to provide patients with treatments that truly address their conditions in a meaningful way. The opportunity to collaborate with esteemed institutions like Max Planck and UMG further strengthens my belief in Scinai's potential. I look forward to contributing to Scinai's mission and helping establish it as a globally recognized leader in scientifically driven drug development".
Amir Reichman, CEO of Scinai, commented: "We are thrilled to welcome Dr. Jonathan Sadeh to our Scientific Advisory Board. His extensive experience and proven track record in drug development and clinical research will be invaluable as we continue to advance our pipeline of innovative I&I biological products. We look forward to his contributions and insights as we strive to bring transformative therapies to patients in need."
About Scinai Immunotherapeutics:
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.
For more information please visit, www.scinai.com.
